Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI app aims to keep heart patients out of the hospital

NCT ID NCT06686056

Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether an artificial intelligence (AI)-enhanced mobile app can help people with coronary heart disease manage their health after leaving the hospital. Over 1,100 participants used the app to track health metrics, receive medication reminders, and get lifestyle tips, while a comparison group received usual care. The main goal was to see if the app helped lower bad cholesterol (LDL-C) within three months, along with improving blood pressure, blood sugar, and medication adherence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-enhanced mobile health app (AIM-CHD)
What this could lead to
If it works, this could provide an effective, scalable way for people with heart disease to manage their condition at home and reduce future heart problems.
What could go wrong
This is a single-center study with 1100 participants, so results may not apply to everyone. The app's success depends on user engagement and may not work for those less comfortable with technology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,100 people

The number who actually took part.

Started

Nov 2024

Finished

Jun 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CHD patients aged 18-85 years * ability of the patient or close relatives to use smartphones and applications * willingness to participate and sign the informed consent form Exclusion Criteria: * severe cognitive impairment * advanced malignant tumors * expected survival of less than 3 months * severe multi-organ failure * refusal to sign the informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Secondary prevention of coronary heart disease

Contacts and locations

Locations

  • Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases

    Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.